dna topoisomerase 1

DNA topoisomerase II inhibitor 1 是 DNA 拓扑异构酶 II 的有效抑制剂，能够将细胞周期停滞在亚 G1 期，并诱导细胞凋亡 (apoptosis) ，具有抗增值作用。

Irinotecan hydrochloride trihydrate (CPT-11 HCl Trihydrate) 通过抑制拓扑异构酶 1 来防止 DNA 展开，可研究结肠癌和直肠癌。

Sophoridine (Dihydro-5-episophocarpine) 是一种从豆科植物槐豆斜生植物的叶子中分离出来的喹喔啉生物碱。它是胰腺癌的候选药物，诱导细胞凋亡。

3-Hydroxypyridine对Sup-T1细胞中的DNA topoisomerase 2-beta（Topo IIβ）和HIV-1复制具有抑制活性，可用于研究HIV-1病毒。

Berberine (Umbellatine) 属于生物碱类天然产物，可以激活 AMPK、抑制 DNA 拓扑异构酶、诱导 ROS 生成。Berberine 具有抗肿瘤、抗菌、降血糖、降血脂等生物学活性。

1,4-Naphthoquinone (P-Naphthoquinone) 被用作单胺氧化酶和 DNA 拓扑异构酶活性的潜在抑制剂，还用于抑制乙酰转移酶活性。

Trovafloxacin 是广谱喹诺酮类抗生素，对革兰氏阳性，革兰氏阴性和厌氧菌有活性。它可阻断 DNA 促旋酶 和拓扑异构酶 IV 的活性。它也是口服活性的 Pannexin 1通道选择性抑制剂，对 PANX1内向电流的 IC50为 4 μM。

Idarubicin 是一种有效的、具有口服活性的蒽环类抗白血病剂。Idarubicin 抑制拓扑异构酶 II，干扰 DNA 复制和 RNA 转录。Idarubicin 可诱导 DNA 损伤。Idarubicin 抑制 DNA 合成和 c-myc 表达。Idarubicin 还抑制细菌和酵母菌的生长。

LMP744 hydrochloride (NSC-706744 hydrochloride) 是一种是拓扑异构酶 1 抑制剂，显示出抗肿瘤的活性。

Trovafloxacin是一种广谱氟喹诺酮类抗生素，可阻断 DNA 促旋酶 (DNA gyrase) 和拓扑异构酶 IV (topoisomerase IV) 的活性，也是一种有效的特异性 pannexin 1 通道抑制剂 (PANX1, IC50 = 4 μM)。

Hycanthone (Etrenol(mesylate)) 是 Lucanthone 的生物活性代谢产物，是一种抗血吸虫病药。它是一个噻吨酮类 DNA 嵌入剂，可抑制 RNA 合成以及 DNA 拓扑异构酶 I 和 II。它通过直接蛋白质结合来抑制核酸生物合成并抑制嘌呤内切核酸酶1，KD 为 10 nM。

Daunorubicinol, a potent antitumor drug-linker conjugate for antibody-drug conjugate (ADC) applications, utilizes Aur0101 (DNA Topoisomerase II inhibitor) connected through the ADC linker[1].

MAC glucuronide phenol-linked SN-38, a pH-sensitive lactone and DNA topoisomerase I inhibitor drug linker, exhibits cytotoxicity in L540cy and Ramos cells, with IC50 values of 113 ng mL and 67 ng mL, respectively[1].

iNOS TopoI-IN-1（compound AuL9）是一种具备多重靶点的杂交分子，表现出抗肿瘤、抗炎及抗氧化的特性。此化合物能有效抑制乳腺癌细胞株MCF-7和MDA MB-231的增长，IC50分别为3.5 μM及6.3 μM，其机制主要是通过抑制人类拓扑异构酶I（TopoI）（Ki=2.72 μM）的活动，导致DNA损伤并诱发细胞凋亡（apoptosis）。同时，iNOS TopoI-IN-1通过降低NF-kB的激活，抑制iNOS表达（Ki=1.49 μM），进一步增强其抗炎作用。

DNA gyrase Topo IV-IN-1 (Compound 27) 是一种抑制 DNA 回旋酶与拓扑异构酶 IV 的活性化合物，具有抑制细菌生长的效果。其对大肠杆菌和对甲氧西林耐药金黄色葡萄球菌的 DNA 回旋酶的IC50分别为 11 nM 和 17 nM；对于拓扑异构酶 IV，IC50为 83 nM 和 21 nM。DNA gyrase Topo IV-IN-1 可用于研究抗感染治疗。

DS-8587 is a DNA topoisomerase inhibitor. DS-8587 exhibits potent antibacterial activity against quinolone-resistant A. baumannii isolates that harbor mutations in quinolone resistance-determining regions. DS-8587 significantly reduces the number of viabl

AZD 1152 is an orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50= 0.36 nM).1AZD 1152 is converted to AZD 1152-HQPA in plasma. Inhibition of Aurora B results in disruption of spindle checkpoint functions and chromosome alignment, resulting in inhibition of cytokinesis followed by apoptosis.2,3AZD 1152 inhibits tumor xenograft growthin vivo.4,5 1.Mortlock, A.A., Foote, K.M., Heron, N.M., et al.Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinaseJ. Med. Chem.50(9)2213-2224(2007) 2.Popescu, R., Heiss, E.H., Ferk, F., et al.Ikarugamycin induces DNA damage, intracellular calcium increase, p38 MAP kinase activation and apoptosis in HL-60 human promyelocytic leukemia cellsMutation Research709-71060-66(2011) 3.Moore, A.S., Blagg, J., Linardopoulos, S., et al.Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemiasLeukemia24(4)671-678(2010) 4.Wilkinson, R.W., Odedra, R., Heaton, S.P., et al.AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosisClin. Cancer. Res13(12)3682-3688(2007) 5.Yang, J., Ikezoe, T., Nishioka, C., et al.AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivoBlood110(6)2034-2040(2007)

TAS-103 is a dual inhibitor of DNA topoisomerase I II, used for cancer research. TAS-103 is a dual inhibitor of DNA topoisomerase I II. TAS-103 (0.1-10 μM) is active on CCRF-CEM cells, with an IC50 value of 5 nM. TAS-103 (0.1 μM) significantly increases levels of topo IIα FITC immunofluorescence in individual CCRF-CEM cells[1]. TAS-103 (0.01-1 μM) is highly cytotoxic to Lewis lung carcinoma (LLC) cells, and Liposomal TAS-103 is almost as active as free TAS-103[2]. TAS-103 inhibits the viability of HeLa cells, with an IC50 of 40 nM. TAS-103 (10 μM) disrupts signal recognition particle (SRP) complex formation, and induces destabilization of SRP14 and SRP19 and its eventual degradation[3]. TAS-103 (30 mg kg, i.v.) causes significant tumor growth suppression in mice bearing Lewis lung carcinoma (LLC) cells, without obvious body weight loss, and the liposomal TAS-103 is more active than free TAS-103[2]. [1]. Padget K, et al. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem Pharmacol. 2000 Sep 15;60(6):817-21. [2]. Shimizu K, et al. Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]aminol-3-hydroxy-7H-indeno[2,1-clquinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent. Biol Pharm Bull. 2002 Oct;25(10):1385-7. [3]. Yoshida M, et al. A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads. Mol Pharmacol. 2008 Mar;73(3):987-94. Epub 2007 Dec 18.

ARN-21934 是高选择性的人拓扑异构酶 II α 抑制剂，具有血脑屏障通透性。依托泊苷抑制 DNA 松弛的IC50为120 μM，ARN-21934 抑制 DNA 松弛的IC50为 2 μM。ARN-21934具有良好的体内药代动力学特性。

Topoisomerase I inhibitor 2 是一种高度选择性的DNA 拓扑异构酶 I(Top1) 抑制剂，可抑制Top1活性并导致 DNA 损伤。Topoisomerase I inhibitor 2 阻断 G2 M 期并诱导细胞凋亡，具有抗肿瘤作用。

Topoisomerase I inhibitor 3 (Compound ZML-14) 诱导 HepG2 细胞凋亡，并在 G2 M 期阻滞细胞周期。Topoisomerase I inhibitor 3 是与拓扑异构酶 I-DNA 复合物相互作用的拓扑异构酶 I 抑制剂。

Topoisomerase II inhibitor 6 (Compound 5) 是色胺酮的衍生物。它是一种有效的拓扑异构酶的选择性抑制剂。Topoisomerase II inhibitor 6 在 G2 期阻断 CCRF-CEM 的细胞周期并诱导 DNA 双链断裂。Topoisomerase II inhibitor 6 对不同的肿瘤细胞系具有抗增殖活性，在癌症疾病研究中具有潜力。

Topoisomerase I II inhibitor 2 (compound 1a) 可显著抑制小鼠模型中的异种移植肿瘤的生长，可用于肝癌治疗。Topoisomerase I II inhibitor 2 是一种DNA 拓扑异构酶 I II 的双重抑制剂。Topoisomerase I II inhibitor 2 是有效的拓扑异构酶抑制剂，对LM9 细胞和Huh7 细胞的 IC50值分别为 6.83 μM 和9.82 μM 。

Type II topoisomerase inhibitor 1 可用于抗菌领域。Type II topoisomerase inhibitor 1 是大肠杆菌DNA 旋转酶的选择性抑制剂，IC50值为 1.7 nM，并能与 Asp73 残基形成氢键。Type II topoisomerase inhibitor 1 抑制拓扑异构酶 IV 的活性，IC50值为 0.98 μM。